Stock listing

NASDAQ:IPSC Century Therapeutics, Inc. Stock

Home listing (NASDAQ) of Century Therapeutics, Inc.

Follow Century Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IPSC

$1.17 USD -0.21 (-15.6%)

Close on Nov 20, 2026

Past year +137.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.16 – $1.32 USDNov 20, 2026
Volume
916,108 sharesNov 20, 2026
Market cap
$211.6M USDAt the close on Nov 20, 2026 · price × 181.6M shares outstanding
52-week range
$0.464 – $3.04 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.21M USDMedian day 608,755 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Century Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IPSC · Home$1.165 USD-0.215 (-15.6%)916,108$1.32$1.32$1.16$1.38Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IPSC · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.165-0.215-15.6%$1.32$1.32$1.16916,108
$1.38+0.01+0.7%$1.36$1.46$1.321,142,209
$1.37-0.27-16.5%$1.64$1.64$1.35695,954
$1.64-0.01-0.6%$1.65$1.705$1.57909,925
$1.65+0.02+1.2%$1.62$1.68$1.565373,172
$1.63-0.11-6.3%$1.75$1.75$1.60608,755
$1.74+0.06+3.6%$1.735$1.75$1.64327,716
$1.68-0.13-7.2%$1.78$1.85$1.63720,025
$1.81+0.13+7.7%$1.71$1.90$1.641,460,093
$1.68+0.17+11.3%$1.52$1.73$1.481,896,472
$1.51-0.16-9.6%$1.66$1.685$1.50561,307
$1.67+0.15+9.9%$1.58$1.77$1.52749,287
$1.52+0.04+2.7%$1.49$1.67$1.43773,524
$1.48+0.01+0.7%$1.49$1.535$1.461,128,455
$1.47+0.01+0.7%$1.46$1.495$1.37951,059
$1.46-0.04-2.7%$1.53$1.55$1.4151,445,878
$1.50+0.05+3.4%$1.44$1.505$1.43839,754
$1.45+0.03+2.1%$1.40$1.48$1.38771,261
$1.42-0.04-2.7%$1.43$1.45$1.39493,653
$1.46-0.12-7.6%$1.55$1.57$1.44892,067
$1.58-0.03-1.9%$1.61$1.75$1.5651,766,209
$1.61-0.03-1.8%$1.65$1.67$1.5251,678,418
$1.64+0.17+11.6%$1.49$1.745$1.401,402,635
$1.47+0.10+7.3%$1.38$1.505$1.32586,235
$1.37-0.13-8.7%$1.50$1.55$1.37722,500
$1.50+0.12+8.7%$1.38$1.52$1.36927,200
$1.380.000.0%$1.36$1.44$1.311,271,300
$1.38-0.06-4.2%$1.44$1.44$1.35544,200
$1.44-0.03-2.0%$1.47$1.51$1.44390,900
$1.47+0.01+0.7%$1.46$1.55$1.42816,800
$1.46+0.18+14.1%$1.26$1.46$1.2191,521,000
$1.28-0.04-3.0%$1.29$1.32$1.27697,200
$1.32-0.16-10.8%$1.48$1.50$1.292,714,200
$1.48-0.05-3.3%$1.58$1.59$1.455771,300
$1.53-0.08-5.0%$1.64$1.67$1.465803,000
$1.61-0.10-5.8%$1.65$1.695$1.595619,400
$1.71+0.06+3.6%$1.67$1.72$1.66623,700
$1.65-0.02-1.2%$1.66$1.67$1.63353,500
$1.670.000.0%$1.66$1.715$1.62409,000
$1.67-0.02-1.2%$1.70$1.78$1.63457,000
$1.69-0.07-4.0%$1.77$1.77$1.68545,200
$1.76-0.13-6.9%$1.89$1.938$1.76508,100
$1.89+0.04+2.2%$1.88$1.94$1.85414,100
$1.85-0.01-0.5%$1.87$1.905$1.829421,000
$1.86-0.02-1.1%$1.88$1.88$1.8151,369,400
$1.88+0.02+1.1%$1.89$1.94$1.83430,200
$1.86-0.12-6.1%$2.00$2.06$1.86839,400
$1.98-0.02-1.0%$2.00$2.00$1.93359,600
$2.00+0.06+3.1%$1.96$2.02$1.89507,600
$1.940.000.0%$1.98$2.00$1.89465,700
$1.94-0.09-4.4%$2.03$2.03$1.91510,000
$2.03-0.04-1.9%$2.07$2.10$2.03293,100
$2.07-0.04-1.9%$2.10$2.13$2.03228,100
$2.11+0.02+1.0%$2.06$2.15$2.06300,000
$2.09-0.02-0.9%$2.13$2.13$2.05349,600
$2.11+0.08+3.9%$2.03$2.135$2.03465,800
$2.03-0.02-1.0%$2.00$2.04$1.98320,500
$2.05+0.025+1.2%$2.00$2.06$1.97373,900
$2.025-0.205-9.2%$2.23$2.25$1.99629,300
$2.23+0.09+4.2%$2.15$2.25$2.15525,700
$2.14-0.03-1.4%$2.17$2.17$2.10313,500
$2.17+0.05+2.4%$2.13$2.205$2.12542,815
$2.12+0.05+2.4%$2.08$2.145$2.03360,771
$2.07+0.05+2.5%$2.05$2.085$2.02330,600
$2.02-0.09-4.3%$2.07$2.09$2.019314,100
Ticker
NASDAQ:IPSC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Century Therapeutics, Inc. news

Century Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 94 in all · newest Nov 12, 2026 · oldest 2021
Decks
35 decks · latest Oct 2, 2026

Where Century Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IPSC · Home listing · This pageNASDAQUnited StatesUSD
BOATS:IPSCBOATSUnited StatesUSD

Valuation

Price/book 1.0× against a median of 1.8×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$131.9M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.2×
Beta vs S&P 500
2.35

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Century Therapeutics, Inc. · NASDAQ:IPSCUS$211.6MUS$131.9Mn/an/an/a1.0×n/a0.2×2.35
ProKidney Corp. · NASDAQ:PROKUS$217.3MUS$77.56Mn/a100×n/an/an/an/a1.61
Pyxis Oncology, Inc. · NASDAQ:PYXSUS$216.5MUS$160.9Mn/an/an/a5.2×n/a0.0×0.89
Oryzon Genomics SA · BME:ORYUS$216.4MUS$206.7Mn/an/an/a1.6×n/a0.1×n/a
Rocket Pharmaceuticals, Inc. · NASDAQ:RCKTUS$214.1M−US$25.02Mn/an/an/a0.7×n/a0.1×1.72
Orum Therapeutics, Inc. · KRX:475830US$212.5MUS$24.22M15.4×n/an/a1.5×n/a0.0×n/a
GemVax & KAEL Co Ltd · KRX:082270US$212.3MUS$207.4Mn/a3.3×21.2×3.8×−14.4%0.4×n/a
Transgene SA · EURONEXT:TNGUS$212.2MUS$112.7Mn/a750×n/a1.8×n/a0.0×n/a
Arcturus Therapeutics Holdings Inc. · NASDAQ:ARCTUS$211.8MUS$45.18Mn/a1.5×n/a1.3×−285.9%0.1×2.01
AnnJi Pharmaceutical Co., Ltd. · TPEX:7754US$209.9MUS$196.0Mn/a855×n/a16.5×n/a0.0×n/a
Racura Oncology Ltd · ASX:RACUS$207.6MUS$184.9Mn/an/an/a8.6×n/a0.0×n/a
Median of the othersUS$212.4MUS$136.8M15.4×100×21.2×1.8×−150.1%0.0×1.67

Forecasts

3 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
4.75 USD · Analysts' mean
EPS, year to Dec 2026
-0.52 · 1 analyst

Team and board

Officers

OfficerRole
Brent PfeiffenbergerPresident and Chief Executive Officer
Krista KauppinenVP, General Counsel & Head of Intellectual Property
Century Therapeutics Douglas Carr SeniorVice President
Elizabeth DevlinVP, Head of Development
Chad CowanChief Scientific Officer
Douglas CarrPrincipal Financial Officer
Greg RussottiChief Technology and Manufacturing Officer
Megan BilsonChief People Officer

Board

DirectorRole
Joseph TruittDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−6.3%
Q2 2026Aug 12, 2026 · Before open−4.8%
Q1 2026May 13, 2026 · Before open−0.4%
Q4 2025Mar 12, 2026−14.3%
Q3 2025Nov 13, 2025 · Before open−17.5%
Q2 2025Aug 14, 2025 · After close+2.1%
Q1 2025May 15, 2025 · After close+8.2%
Q4 2024Mar 19, 2025−6.5%
Q3 2024Nov 5, 2024 · Before open+5.6%
Q2 2024Aug 8, 2024 · Before open+4.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−1.0%
Q4 2023Mar 14, 2024 · Before open−7.2%
Q3 2023Nov 9, 2023 · Before open−13.1%
Q2 2023Aug 9, 2023 · Before open−1.7%
Q1 2023May 11, 2023 · Before open−1.8%
Q4 2022Mar 16, 2023 · Before open−1.2%
Q3 2022Nov 10, 2022 · Before open+15.1%
Q2 2022Aug 11, 2022 · Before open−3.7%
Q1 2022May 16, 2022 · Before open+9.8%
Q4 2021Mar 17, 2022 · Before open−1.0%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (October 2026)Technical19 slidesOct 2, 2026
Investor Presentation (August 2026)Investor deck31 slidesAugust 2026
Technical Presentation (June 2026)Technical17 slidesJun 8, 2026
Corporate Update (March 2026)Corporate update38 slidesMar 12, 2026
Investor Presentation (January 2026)Investor deck38 slidesJan 12, 2026
Investor Presentation (January 2026)Investor deck36 slidesJan 8, 2026
Technical Presentation (2026)Technical19 slides2026
Investor Presentation (December 2025)Investor deck35 slidesDec 12, 2025
Investor Presentation (November 2025)Investor deck34 slidesNov 13, 2025
Investor Presentation (August 2025)Investor deck36 slidesAug 14, 2025
All 35 decks
DeckKindSlidesDate
Investor Presentation (May 2025)Investor deck39 slidesMay 15, 2025
Corporate Update (March 2025)Corporate update35 slidesMar 19, 2025
Investor Presentation (January 2025)Investor deck32 slidesJan 13, 2025
Investor Presentation (November 2024)Investor deck31 slidesNov 5, 2024
Investor Presentation (August 2024)Investor deck33 slidesAug 8, 2024
Investor Presentation (June 2024)Investor deck33 slidesJun 3, 2024
Investor Presentation (April 2024)Investor deck33 slidesApr 11, 2024
Investor Presentation (March 2024)Investor deck35 slidesMar 14, 2024
Technical Presentation (December 2023)Technical32 slidesDec 11, 2023
Investor Presentation (November 2023)Investor deck28 slidesNov 9, 2023
Investor Presentation (October 2023)Investor deck25 slidesOct 3, 2023
Investor Presentation (August 2023)Investor deck25 slidesAug 9, 2023
Investor Presentation (March 2023)Investor deck24 slidesMar 20, 2023
Investor Presentation (January 2023)Investor deck26 slidesJan 9, 2023
Investor Presentation (November 2022)Investor deck27 slidesNov 30, 2022
Investor Day (November 2022)Investor day66 slidesNov 10, 2022
Investor Presentation (September 2022)Investor deck23 slidesSep 8, 2022
Investor Day (June 2022)Investor day76 slidesJun 13, 2022
B of A Securities 2022 Healthcare ConferenceConference8 slidesMay 10, 2022
21st Annual Needham Virtual Healthcare Conference (April 2022)Conference17 slidesApr 13, 2022
J.P. Morgan Annual Healthcare Conference 2022Conference14 slidesJan 11, 2022
Technical Presentation (December 2021)Technical62 slidesDec 16, 2021
Investor Presentation (November 2021)Investor deck21 slidesNov 18, 2021
Investor Presentation (October 2021)Investor deck23 slidesOct 13, 2021
Investor Presentation (August 2021)Investor deck15 slidesAug 12, 2021

Open Decks

Financings

RaiseDate
Private placement of shares of common stock (or pre-funded warrants) and accompanying warrants
Announced: about US$135M · US$1.15 a share · Warrants at US$2.6 · Leerink Partners +2
Dealers: Leerink Partners, TD Cowen, Mizuho
Buyers: TCGX; RA Capital Management; Commodore Capital; Deep Track Capital; RTW Investments; Venrock Healthcare Capital Partners; T1D Fund
Use of proceeds: Fund development of lead product candidate CNTY-813, working capital and general corporate purposes
Jan 8, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$20.00 a share on Jun 17, 2021.

Price
US$20.00 a share
Shares offered
10,550,000 shares of common stock
Offering size
US$211 million
Underwriters' option
Up to 1,582,500 more shares
Listing
IPSC on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, BofA Securities, SVB Leerink, Piper Sandler · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMar 26, 2021
Filed publiclyMay 28, 2021
Amended twiceNewest Jun 15, 2021
Shares registered with an exchangeJun 14, 2021
Declared effective by the SECJun 17, 2021
Final prospectus, with the priceJun 21, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2016FY2015
Revenue109.2M6.59M2.23M5.20M1.06M00470.3M950.8M
Cost of revenue13.1M13.3M13.0M10.1M4.58M1.75M249.0K467.8M888.8M
Gross profit96.1M6.59M2.23M5.20M-4.58M-1.75M-249.0K2.48M62.0M
Research and development95.7M107.2M92.7M97.2M75.6M39.7M14.3M9.09M11.4M
Selling, general and administrative24.0M33.2M34.7M31.9M19.2M9.49M5.77M81.4M108.8M
Operating income-17.3M-138.1M-146.5M-133.8M-94.9M-53.9M-20.0M
Depreciation and amortization13.1M13.3M13.0M8.44M3.75M1.40M249.0K
EBITDA-4.17M-124.8M-133.5M-125.4M-91.1M-52.5M-19.8M
Interest expense0540.0K1.02M1.27M381.0K000
Income before tax-9.65M-124.8M-134.8M-130.8M-95.8M-53.6M-244.8M
Income tax-68.0K1.79M1.88M91.0K43.0K1.08M1.21M
Net income-9.58M-126.6M-136.7M-130.9M-95.8M-53.6M-244.8M
Earnings per share, basic-0.14-1.61-2.30-2.27-2.96-7.16-4.46
Earnings per share, diluted-0.14-1.61-2.30-2.96-2.96-7.16

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2016FY2015
Cash and equivalents61.9M58.4M47.3M84.3M56.4M27.2M44.1M21.5M208.0K
Short-term investments55.3M130.9M125.4M231.2M166.4M48.5M37.5M
Receivables667.0K1.52M665.0K780.0K250.0K908.0K123.0K
Inventory-250.0K1.88M2.34M192.9M285.8M
Current assets120.8M194.1M177.0M319.7M228.2M78.8M84.1M
Property, plant and equipment50.0M62.1M71.7M82.8M58.0M15.4M2.49M402.1M440.9M
Total assets223.7M353.2M360.7M486.5M437.4M106.8M90.9M758.0M844.7M
Accounts payable4.77M3.08M2.74M5.45M7.60M8.08M1.55M55.9M43.0M
Current liabilities20.2M129.8M17.8M29.8M15.7M12.1M2.99M289.7M317.4M
Long-term debt3.74M8.90M9.64M275.4M156.3M
Total debt43.6M53.8M48.2M10.4M10.4M9.64M
Total liabilities64.8M191.9M175.9M183.8M41.1M33.4M182.8M575.5M485.0M
Shareholders' equity158.9M161.4M184.8M302.7M396.2M-106.4M-91.9M182.5M359.7M
Shares outstanding87.5M85.8M60.3M55.0M58.5M7.48M54.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2016FY2015
Cash from operations-103.9M-110.1M-88.3M14.1M-89.0M-41.3M-16.2M104.3M
Capital spending-848.0K-154.0K-13.7M-30.6M-45.0M-9.82M-2.46M-11.1M-29.4M
Free cash flow-104.7M-110.3M-102.1M-16.6M-134.0M-51.1M-18.6M74.9M
Cash from investing107.5M47.5M61.1M-13.1M-298.3M-22.8M-19.8M
Cash from financing173.0K74.6M-9.72M27.2M417.8M47.7M74.8M98.1M
Share buybacks27.2M223.9M
Change in cash3.80M11.9M-36.9M28.1M30.4M-16.3M38.8M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 17, 2026Insider tradeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
8-K · Current reportOct 2, 2026Current reportSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2026Insider tradeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
8-K · Current reportSep 9, 2026Management or board changeSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
8-K · Current reportAug 12, 2026ResultsSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
8-K · Current reportJun 16, 2026Management or board changeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Meeting outcomeSEC
144 · Notice of proposed saleJun 12, 2026Other filingsSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
8-K · Current reportJun 8, 2026Current reportSEC
144 · Notice of proposed saleJun 8, 2026Other filingsSEC
424B7 · ProspectusMay 21, 2026Offer documentSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 13, 2026ResultsSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 16, 2026Annual reportSEC
PRE 14A · Preliminary proxy statementApr 16, 2026Meeting noticeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
8-K · Current reportMar 26, 2026Current reportSEC
424B5 · ProspectusMar 26, 2026Offer documentSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
144 · Notice of proposed saleMar 12, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
8-K · Current reportMar 12, 2026ResultsSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveFeb 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
UPLOAD · Letter from the SECFeb 17, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 17, 2026Other filingsSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
S-3 · Registration statementFeb 5, 2026Offer documentSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
8-K · Current reportJan 23, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeJan 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 15, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJan 12, 2026Other filingsSEC
8-K · Current reportJan 8, 2026Material contractSEC
CORRESP · Letter to the SECJan 7, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
S-3/A · Registration statement, amendedJan 5, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeJan 5, 2026Big-stake noticeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
8-K · Current reportDec 29, 2025Management or board changeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
8-K · Current reportDec 12, 2025Current reportSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
144/A · Notice of proposed sale, amendedDec 9, 2025Other filingsSEC
8-K · Current reportDec 9, 2025Management or board changeSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
DEFA14A · Additional proxy materialDec 2, 2025Meeting noticeSEC
DEF 14A · Proxy statementDec 2, 2025Meeting noticeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementNov 21, 2025Meeting noticeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
144 · Notice of proposed saleSep 8, 2025Other filingsSEC
144 · Notice of proposed saleSep 8, 2025Other filingsSEC
8-K · Current reportAug 29, 2025Current reportSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
4 · Change in ownershipAug 6, 2025Insider tradeSEC
UPLOAD · Letter from the SECJul 14, 2025Other filingsSEC
S-3 · Registration statementJul 10, 2025Offer documentSEC
8-K · Current reportJul 7, 2025Management or board changeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
8-K · Current reportJun 16, 2025Meeting outcomeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
144 · Notice of proposed saleJun 9, 2025Other filingsSEC
144 · Notice of proposed saleJun 9, 2025Other filingsSEC
144 · Notice of proposed saleJun 9, 2025Other filingsSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
144 · Notice of proposed saleMay 16, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
144 · Notice of proposed saleMay 5, 2025Other filingsSEC
ARS · Annual report to shareholdersApr 22, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 20, 2025Offer documentSEC
8-K · Current reportMar 19, 2025ResultsSEC
10-K · Annual reportMar 19, 2025Annual reportSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
144 · Notice of proposed saleMar 10, 2025Other filingsSEC
144 · Notice of proposed saleMar 10, 2025Other filingsSEC
144 · Notice of proposed saleMar 10, 2025Other filingsSEC
8-K · Current reportFeb 28, 2025Current reportSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
8-K · Current reportJan 13, 2025ResultsSEC
8-K · Current reportDec 13, 2024Current reportSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 27, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
8-K · Current reportNov 5, 2024ResultsSEC
10-Q · Quarterly reportNov 5, 2024Quarterly reportSEC
144 · Notice of proposed saleNov 4, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedOct 25, 2024Big-stake noticeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 3, 2024Insider tradeSEC
8-K · Current reportSep 26, 2024Management or board changeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
8-K · Current reportAug 8, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
4 · Change in ownershipAug 7, 2024Insider tradeSEC
4 · Change in ownershipAug 7, 2024Insider tradeSEC
144 · Notice of proposed saleAug 5, 2024Other filingsSEC

This page holds 200 of 447 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Century Therapeutics, Inc.’s releases · as of Nov 5, 2026

Common shares
181,597,002
Fully diluted
181,597,002

Fully diluted

LineSharesAs of
Common shares181,597,002Nov 5, 2026

Share count over time

CountShares
Nov 5, 2026181,597,002

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
TCG Crossover Management, LLC17.8M9.8%US$30.4MSep 30, 2026
Ra Capital Management, L.P.17.8M9.8%US$30.4MSep 30, 2026
Versant Venture Management, LLC12.2M6.7%US$20.8MSep 30, 2026
Deep Track Capital, LP9.46M5.2%US$16.2MSep 30, 2026
BlackRock8.89M4.9%US$15.2MSep 30, 2026
Commodore Capital LP8.7M4.8%US$14.9MSep 30, 2026
Venrock Adviser, LLC8.7M4.8%US$14.9MSep 30, 2026
Rtw Investments, LP8.7M4.8%US$14.9MSep 30, 2026
Vanguard7.51M4.1%US$12.8MSep 30, 2026
Millennium6.05M3.3%US$10.4MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Woodline Partners LP5.66M3.1%US$9.68MSep 30, 2026
Balyasny Asset Management L.P.5.52M3.0%US$9.44MSep 30, 2026
Point72 Asset Management, L.P.5.11M2.8%US$8.74MSep 30, 2026
Seven Fleet Capital Management LP4.42M2.4%US$6.08MSep 30, 2026
Trails Edge Capital Partners, LP4.13M2.3%US$7.07MSep 30, 2026
Spruce Street Capital LP4.06M2.2%US$6.94MSep 30, 2026
Adage Capital Partners Gp, L.L.C.3.79M2.1%US$6.48MSep 30, 2026
Geode Capital2.87M1.6%US$4.91MSep 30, 2026
Stempoint Capital LP2.56M1.4%US$4.38MSep 30, 2026
Two Sigma2.56M1.4%US$4.38MSep 30, 2026
State Street2.51M1.4%US$4.3MSep 30, 2026
DAFNA Capital Management LLC2.39M1.3%US$4.08MSep 30, 2026
Northern Trust1.48M0.81%US$2.53MSep 30, 2026
Rock Springs Capital Management LP1.3M0.72%US$2.23MSep 30, 2026
Casdin Capital, LLC1.23M0.68%US$2.1MSep 30, 2026
Renaissance Technologies1.07M0.59%US$1.84MSep 30, 2026
Longaeva Partners L.P.943K0.52%US$1.61MSep 30, 2026
UBS804K0.44%US$1.38MSep 30, 2026
Goldman Sachs461K0.25%US$788KSep 30, 2026
Invesco403K0.22%US$689KSep 30, 2026
Schwab379K0.21%US$648KSep 30, 2026
Dimensional319K0.18%US$544KSep 30, 2026
BNY299K0.16%US$511KSep 30, 2026
Fidelity273K0.15%US$467KSep 30, 2026
American Century232K0.13%US$397KSep 30, 2026
Nuveen164K0.09%US$280KSep 30, 2026
Morgan Stanley145K0.08%US$247KSep 30, 2026
Spark Investment Management LLC128K0.07%US$219KSep 30, 2026
Integrated Quantitative Investments LLC128K0.07%US$219KSep 30, 2026
Rhumbline Advisers126K0.07%US$215KSep 30, 2026
Graham Capital Management, L.P.120K0.07%US$206KSep 30, 2026
Squarepoint Ops LLC110K0.06%US$189KSep 30, 2026
DWS105K0.06%US$180KSep 30, 2026
T. Rowe Price101K0.06%US$173KSep 30, 2026
Bank of America101K0.06%US$173KSep 30, 2026
Raymond James Financial Inc91,3230.05%US$156KSep 30, 2026
Citadel84,6600.05%US$145KSep 30, 2026
Wealth Enhancement Advisory Services, LLC78,1860.04%US$114KSep 30, 2026
RBC77,0140.04%US$132KSep 30, 2026
JPMorgan60,7930.03%US$100KSep 30, 2026

This page holds 50 of 98 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund4.34M2.4%US$10.6MJun 30, 2026
iShares Russell 2000 ETF2.9M1.6%US$7.11MJun 30, 2026
Fidelity Small Cap Index Fund1.34M0.74%US$2.71MJul 31, 2026
Vanguard Extended Market Index Fund1.22M0.67%US$3MJun 30, 2026
iShares Russell 2000 Value ETF1.11M0.61%US$2.71MJun 30, 2026
Fidelity Extended Market Index Fund560K0.31%US$1.37MMay 31, 2026
Small Cap Value Fund550K0.30%US$1.35MJun 30, 2026
iShares Micro-Cap ETF413K0.23%US$1.01MJun 30, 2026
Schwab Small-Cap Index Fund299K0.16%US$605KJul 31, 2026
Master Small Cap Index Series230K0.13%US$564KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Total Market Index Fund200K0.11%US$491KMay 31, 2026
Fidelity Small Cap Value Index Fund172K0.09%US$422KJun 30, 2026
Fidelity Series Total Market Index Fund164K0.09%US$402KMay 31, 2026
Nuveen Small Cap Blend Index Fund164K0.09%US$330KJul 31, 2026
EQ/2000 Managed Volatility Portfolio131K0.07%US$321KJun 30, 2026
Avantis U.S. Small Cap Equity ETF125K0.07%US$307KMay 31, 2026
Dimensional U.S. Small Cap ETF122K0.07%US$246KJul 31, 2026
Fidelity Nasdaq Composite Index Fund112K0.06%US$276KMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF94,8220.05%US$192KJul 31, 2026
LVIP State Street Small-Cap Index Fund90,5000.05%US$222KJun 30, 2026
Schwab Total Stock Market Index Fund79,4150.04%US$160KJul 31, 2026
Vanguard Balanced Index Fund76,0040.04%US$186KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund65,1790.04%US$160KJun 30, 2026
Small Cap Index Fund63,7390.04%US$156KJun 30, 2026
Global X Russell 2000 ETF58,6250.03%US$118KJul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio45,8000.03%US$112KJun 30, 2026
MetLife Russell 2000 Index Portfolio43,2320.02%US$106KJun 30, 2026
ATM Small Cap Managed Volatility Portfolio37,1390.02%US$90,991Jun 30, 2026
Small-Cap Index Portfolio34,9200.02%US$85,554Jun 30, 2026
1290 VT Micro Cap Portfolio27,7320.02%US$67,943Jun 30, 2026
NVIT Small Cap Index Fund27,2000.01%US$66,640Jun 30, 2026
U.S. Micro Cap Portfolio26,9050.01%US$54,348Jul 31, 2026
Small Cap Index Trust25,8480.01%US$63,328Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund21,2780.01%US$42,982Jul 31, 2026
DWS Small Cap Index VIP19,3340.01%US$47,368Jun 30, 2026
1290 VT Small Cap Value Portfolio18,8370.01%US$46,151Jun 30, 2026
T. Rowe Price Small-Cap Index Fund18,5820.01%US$45,526Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund17,800<0.01%US$43,610Jun 30, 2026
BlackRock Small Cap Index V.I. Fund16,539<0.01%US$40,521Jun 30, 2026
Voya RussellTM Small Cap Index Portfolio15,270<0.01%US$37,412Jun 30, 2026
SA Small Cap Index Portfolio14,432<0.01%US$29,153Jul 31, 2026
Victory Extended Market Index Fund14,101<0.01%US$28,484Jul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio11,185<0.01%US$27,403Jun 30, 2026
Nationwide Small Cap Index Fund10,846<0.01%US$21,909Jul 31, 2026
EQ/AB Small Cap Growth Portfolio9,930<0.01%US$24,329Jun 30, 2026
EQ/Small Company Index Portfolio9,930<0.01%US$24,329Jun 30, 2026
Venerable Small Cap Index Fund9,855<0.01%US$24,145Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF9,543<0.01%US$19,277Jul 31, 2026
Dimensional US Core Equity Market ETF9,378<0.01%US$18,944Jul 31, 2026
SmallCap Value Fund II9,238<0.01%US$18,661Jul 31, 2026

This page holds 50 of 70 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Carr Douglas
Officer: SVP Finance & Operations
Sale266USD 1.52US$404Nov 3, 2026
Carr Douglas
Officer: SVP Finance & Operations
Sale1,658USD 1.93US$3,200Sep 14, 2026
Russotti Gregory
Officer: See Remarks
Sale2,587USD 1.93US$4,993Sep 14, 2026
Carr Douglas
Officer: SVP Finance & Operations
Sale254USD 2.05US$521Sep 8, 2026
Russotti Gregory
Officer: See Remarks
Sale534USD 2.05US$1,095Sep 8, 2026
Carr Douglas
Officer: SVP Finance & Operations
Sale275USD 1.98US$545Aug 3, 2026
Carr Douglas
Officer: SVP Finance & Operations
Sale1,654USD 2.23US$3,688Jun 12, 2026
Russotti Gregory
Officer: See Remarks
Sale2,584USD 2.23US$5,762Jun 12, 2026
Carr Douglas
Officer: SVP Finance & Operations
Sale249USD 2.11US$525Jun 8, 2026
Russotti Gregory
Officer: See Remarks
Sale524USD 2.11US$1,106Jun 8, 2026
All 11 trades
TradeTradeSharesPriceValueDate
Carr Douglas
Officer: SVP Finance & Operations
Sale264USD 2.34US$618May 4, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.9.90%17.9MJan 9, 2026Schedule 13G
Chen Yu9.90%17.8MJan 9, 2026Schedule 13G
Deep Track Capital, LP7.34%13.5MJan 8, 2026Schedule 13G
Rtw Investments, LP7.10%13MMar 31, 2026Schedule 13G
Venrock Healthcare Capital Partners III, L.P.7.10%13MJan 9, 2026Schedule 13G
Commodore Capital LP7.10%13MJan 9, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Timothy P. Walbert
Other companies: Latigo Biotherapeutics, Inc. (Chair, Board of Directors · Since at least Aug 6, 2026); Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 24, 2025); Sagimet Biosciences Inc. - Series A (Director · Since at least Apr 1, 2024); Mirum Pharmaceuticals, Inc. (Director · Since at least Apr 5, 2023); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2022 · Past); Assertio Holdings, Inc. (Director · May 20, 2020 – May 20, 2020 · Past); Exicure, Inc. (Director · Jul 22, 2019 – Jun 2, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Oct 12, 2015 – Feb 13, 2018 · Past); Egalet Corporation (Director · Mar 10, 2014 – May 20, 2020 · Past); Horizon Pharma PLC (Chairman, President and CEO, Director · Jul 28, 2011 – Mar 23, 2019 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Mar 13, 2014 · Past); Idm Pharma Inc (President and CEO, Director · May 25, 2007 – Apr 3, 2008 · Past)
Director · Since at least Oct 1, 2022
Eli Casdin
Other companies: GeneDx Holdings Corp. (Board Member · Since at least Apr 27, 2022); Standard BioTools Inc. (Director · Since at least Apr 4, 2022); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past); EQRx Inc (Director · Sep 30, 2022 – Sep 30, 2022 · Past); Tenaya Therapeutics, Inc. (Director · Jun 10, 2022 – Nov 17, 2022 · Past); Absci Corporation (Director · Jun 8, 2022 – Jun 8, 2022 · Past)
Director · Jun 9, 2022 – Jun 9, 2022 · Past
Cynthia M. Butitta
Other companies: Autolus Therapeutics plc (Chair of the Compensation Committee, Member of the Audit Committee · Since at least Mar 18, 2026); Olema Pharmaceuticals, Inc. (Director · Since at least Aug 12, 2020); UroGen Pharma Ltd. (of the Audit Committee · Since at least Jan 1, 2019); Kite Pharma Inc (Chief Operating Officer · Jun 19, 2014 – Oct 3, 2017 · Past)
Director · Since at least Jun 17, 2021
Alessandro Riva
Other companies: BeOne Medicines Ltd. Class A (Director · Since at least May 22, 2026); Bicycle Therapeutics PLC (Director · Since at least Jan 2, 2026)
Director · Since at least Jun 12, 2025
Brent Pfeiffenberger
Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least May 13, 2026); Butterfly Network, Inc. (President and CEO, Director · Mar 7, 2024 – Mar 7, 2024 · Past)
President and CEO, Director · Since at least Dec 4, 2023
Daphne Quimi
Other companies: Amylyx Pharmaceuticals, Inc. (Director · Since at least Jan 6, 2022); Amicus Therapeutics Inc (Chief Financial Officer · Oct 1, 2020 – Jan 17, 2023 · Past)
Director · Since at least Oct 1, 2022
Kimberly Blackwell
Other companies: Monte Rosa Therapeutics, Inc. (Chief Development Officer, Nucleus RadioPharma · Since at least Apr 12, 2021); Zentalis Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jul 1, 2020 – Feb 1, 2024 · Past)
Director · Since at least Jun 17, 2021
Luis Borges
Other companies: Metagenomi Therapeutics, Inc. (Chief Scientific Officer · Feb 8, 2024 – Apr 1, 2024 · Past); Five Prime Therapeutics Inc (SVP, Research · Sep 8, 2016 – Mar 1, 2017 · Past)
Chief Scientific Officer · Jun 17, 2021 – Apr 3, 2023 · Past
Joseph Truitt
Other companies: Larimar Therapeutics, Inc. (BOARD CHAIR · Since at least May 10, 2022)
Director · Since at least Sep 9, 2026
Adrienne FaridChief Operations Officer · Since at least Jun 17, 2021
All 21 people
PersonSeat
Century Therapeutics Douglas Carr SeniorVice President · Since at least Oct 14, 2026
Chad CowanChief Scientific Officer · Since at least Nov 13, 2025
Douglas CarrSVP Finance & Operations · Since at least Jun 17, 2021
Elizabeth DevlinVP, Head of Development · Since at least Nov 5, 2026
Gregory RussottiSee Remarks · Since at least Jun 9, 2025
Greg RussottiChief Technology and Manufacturing Officer · Since at least Nov 4, 2026
Krista KauppinenVP, General Counsel & Head of Intellectual Property · Since at least Nov 5, 2026
Martin Patrick MurphyDirector · Since at least Dec 9, 2025
Megan BilsonChief People Officer · Since at least Nov 5, 2026
Morgan ConnChief Finanical Officer · Oct 14, 2024 – Mar 11, 2025 · Past
Rizzuto CarloDirector · Since at least Jun 12, 2025

Open People

Log in to ask 6ix AI your own questions about Century Therapeutics, Inc.